Merck & Co. Executive Director Of Experimental Medicine Gary Herman: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Firm’s head of experimental medicine talks about his mission to cut Merck’s R&D costs by failing earlier in the preclinical discovery process.
You may also be interested in...
Merck’s type 2 diabetes treatment is approved a few weeks before the estimated user fee date of Novartis’ Galvus.
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.